Marksans Pharma net jumps up by 56% to Rs. 31 cr

Marksans Pharma has posted impressive performance during the second quarter ended September 2014 and its consolidated net profit increased by 55.7 per cent to Rs. 31.16 crore from Rs. 20.01 crore in the similar period of last year. Its EBDITA also moved up by 71.8 per cent to Rs. 50.96 crore from Rs. 29.66 crore. EPS worked out to Rs. 0.82 as against Rs. 0.53 in the last period.

The company's consolidated net sales for the first six months ended September 2014 increased by 35.3 per cent to Rs. 413 crore from Rs. 305 crore and its net profit moved up by 46 per cent to Rs. 56.63 crore from Rs. 38.79 crore in the corresponding period of last year. Its formulations business in Europe increased by 43 per cent to Rs. 271.20 crore from Rs. 189.70 crore and its US & North America formulation revenue improved by 46.7 per cent to Rs. 76.46 crore. Its revenue in Australia and New Zealand touched to Rs. 41.10 crore.

Takeda - Wipro strtegic partnership

Wipro Ltd., the information technology leader has entered into a  strategic partnership with Takeda Pharmaceutical Company Ltd., the largest pharmaceutical company in Japan and one of the global leaders of the industry.

The  strategic partnership will build advanced value in Takeda's operations by consolidating IT platforms across the organisation. As a strategic partner, Wipro will build and maintain an “as-a-service” global platform for Takeda that will drive synergies across its global entities through standardisation of IT architecture.

 Wipro will be primary provider of IT Infrastructure management services covering Takeda’s entities across the world, touching 30,000 users in 16 different languages, operating out of data centers in Asia, Europe and America.



According to Sangita Singh, chief executive Healthcare and Life Science Business Unit at Wipro, the partnership with Takeda is for a business transformation.  Wipro is leveraging its experience in enabling global pharma companies to achieve a leaner & standardized IT workplace and implement newer business models that put patient at the core. We look forward to collaboratively partnering with the Takeda team in enabling this unique platform across its global operations.